| cyclosporine / Generic mfg. |
NCT04895423: Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood |
|
|
| Not yet recruiting | 4 | 160 | RoW | Methotrexate therapy, Mycophenolate mofetil therapy, Cyclosporine therapy, Dupilumab therapy | National Medical Research Center for Children's Health, Russian Federation | Atopic Dermatitis | 07/23 | 07/23 | | |
ChiCTR2200063335: Efficacy and safety of upadacitinib in the treatment of moderate to severe atopic dermatitis |
|
|
| Not yet recruiting | 4 | 64 | | Upadacitinib + TCS ;Cyclosporine +TCS | Longgang district Central Hospital; Longgang district Central Hospital, self-funded | atopic dermatitis | | | | |
2020-004194-51: A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate to severe atopic dermatitis. Badanie kliniczne oceniające skuteczność i bezpieczeństwo stosowania leków - cyklosporyny i metotreksatu u dzieci i młodzieży z atopowym zapaleniem skóry o nasileniu umiarkowanym do ciężkiego. |
|
|
| Not yet recruiting | 3 | 317 | Europe | Cyclosporin, Methotrexate, Mometasone furoate, Tacrolimus, Oral solution, Ointment | Medical University of Lodz, Medical Research Agency | Atopic dermatitis Atopowe Zapalenie Skóry, Atopic dermatitis Atopowe Zapalenie Skóry, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
BREEZE-AD4, NCT03428100 / 2017-004574-34: A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
|
|
| Completed | 3 | 463 | Europe, Japan, RoW | Baricitinib, LY3009104, Placebo, Topical corticosteroid | Eli Lilly and Company, Incyte Corporation | Atopic Dermatitis | 11/19 | 04/23 | | |
|
NCT05149313 / 2021-002967-23: A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine |
|
|
| Completed | 3 | 331 | Europe | Lebrikizumab, Lebrikizumab-matching Placebo | Almirall, S.A. | Dermatitis, Atopic, Eczema | 01/23 | 05/24 | | |
|
ChiCTR1800015455: Lidocaine intravenous infusion versus cyclosporine in treatment of severe atopic dermatitis aged 12-70: a multicentered, randomized, paralleled trial |
|
|
| Not yet recruiting | N/A | 120 | | lidocaine intravenous infusion ;oral cyclosporine | Shanghai Jiaotong University School of Medecin, Xinhua hospital; Shanghai Jiaotong University School of Medecin, Xinhua hospital, Shanghai Jiaotong University School of Medecin | Atopic dermatitis | | | | |
| Recruiting | N/A | 2500 | Europe | Ciclosporin, Methotrexate, Dupilumab, Corticosteroids, Omalizumab, Baricitinib, Upadacitinib, Tralokimumab, Topical corticosteroids | Fundación Academia Española de Dermatología | Dermatitis, Atopic | 01/29 | 01/29 | | |
